Libris Innovations, the for-profit subsidiary of the Indiana Biosciences Research Institute (IBRI), has appointed Ramani Varanasi as Chief Executive Officer.

In this role, Varanasi will lead Libris Innovations’ efforts to advance and support new ventures originating from IBRI and partner innovation, while providing advisory counsel to help early-stage biotechnology companies attract the capital and talent needed to succeed.

“Ramani’s appointment marks an important step for Libris Innovations,” said Alan Palkowitz, PhD, IBRI President and CEO. “Her leadership and experience will be instrumental in accelerating the translation of research into companies that deliver meaningful benefits for patients in need.”

Experience

A scientist, seasoned executive, and entrepreneur, Varanasi brings more than three decades of experience shaping and advancing innovation across the biopharmaceutical industry, working with organizations of all sizes to bridge scientific insight and business value. Her experience spans multiple disease areas and therapeutic approaches, from small-molecule and biologic programs to next-generation genetic and cell-based therapies.

Most recently, Varanasi served as Executive-in-Residence at University of California at San Francisco Innovation Ventures, where she worked closely with innovators and early-stage companies to support venture creation and commercialization efforts. She also serves as an advisor and board member to multiple biotechnology organizations, contributing expertise in company strategy, governance, and growth. Earlier in her career, she served as chief executive officer of companies focused on both drug development and advisory services for emerging biotech ventures.

“Libris Innovations builds on the strong research engine the IBRI has established, with a clear focus on translating that work into new companies and, ultimately, therapies for patients,” said Varanasi. “By launching new ventures and strengthening the biotech ecosystem in Indianapolis and beyond, we can move promising science forward one company at a time.”